J F Forbes
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gnant M, Dubsky P, Cuzick J, Dowsett M, Forbes J, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386:1341-52.
Jul 23, 2015Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Jul 23, 2015Lancet 2015; 386:1341-52
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann Beat, van de Velde C, Pan H, Peto R, Davies C, Gnant M, Dubsky P, Cuzick J, Dowsett M, Forbes J F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R C, Gray R
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.
Dec 5, 2013Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Dec 5, 2013Breast Cancer Res Treat 2013; 143:159-69
Huober J, Thürlimann Beat, Gelber R D, Colleoni M, Coates A S, Goldhirsch A, Price K N, Wardley A, Smith I, Láng I, Neven P, Forbes J F, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B F, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Karlsson P, Gruber G, Goldhirsch A, Gelber R, Forbes J, Castiglione-Gertsch M, Crivellari D, Thürlimann B, Kovács A, Collins J, Lindtner J, Price K, Chua B, Cole B, International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23:2852-8.
Jul 9, 2012Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Jul 9, 2012Ann Oncol 2012; 23:2852-8
Karlsson P, Gruber G, Goldhirsch A, Gelber R D, Forbes J F, Castiglione-Gertsch M, Crivellari D, Thürlimann Beat, Kovács A, Collins J P, Lindtner J, Price K N, Chua B H, Cole B F, International Breast Cancer Study Group
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.
Feb 18, 2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Feb 18, 2011Ann Oncol 2011; 22:2201-2207
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Rabaglio M, Coates A, Goldhirsch A, Gelber R, Smith I, Láng I, Nogaret J, Pienkowski T, Colleoni M, Paridaens R, Forbes J, Campone M, Mouridsen H, Thürlimann B, Hawle H, Castiglione-Gertsch M, Price K, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489-98.
Sep 1, 2009Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Sep 1, 2009Ann Oncol 2009; 20:1489-98
Rabaglio M, Coates A S, Goldhirsch A, Gelber R D, Smith I, Láng I, Nogaret J-M, Pienkowski T, Colleoni M, Paridaens R J, Forbes J F, Campone M, Mouridsen H, Thürlimann Beat, Hawle H, Castiglione-Gertsch M, Price K N, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
Jan 15, 2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Jan 15, 2008BJC 2008; 98:25-33
Bernhard J, Coates A S, Goldhirsch A, Price K N, Castiglione-Gertsch M, Gelber R D, Colleoni M, Green M D, Thürlimann Beat, Yeo W, Aebi S, Forbes J F, Hürny C, Basser R, Martinelli G, Zhang J J, Zahrieh D, International Breast Cancer Study Group
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
May 1, 2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
May 1, 2007Ann Oncol 2007; 18:859-67
Mauriac L, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R D, Nogaret J-M, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann Beat, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. BJC 2004; 91:1893-901.
Nov 29, 2004Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Nov 29, 2004BJC 2004; 91:1893-901
Bernhard J, Goldhirsch A, Price K N, Fey M F, Thürlimann Beat, Veronesi A, Crivellari D, Rudenstam C-M, Snyder R, Collins J, Perey L, Forbes J F, Murray E, Castiglione-Gertsch M, Gelber R D, Coates A S, Zahrieh D, Hürny C
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
Wallgren A, Collins J, Coates A, Price K, Forbes J, Werner I, Fey M, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Goldhirsch A, Gelber R, Bonetti M, International Breast Cancer Study Group Trials I through VII. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13.
Apr 1, 2003Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII
Apr 1, 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1205-13
Wallgren A, Collins J, Coates A S, Price K, Forbes J F, Werner I D, Fey M, Thürlimann Beat, Lindtner J, Holmberg S B, Castiglione-Gertsch M, Goldhirsch A, Gelber R D, Bonetti M, International Breast Cancer Study Group Trials I through VII
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)
Bernhard J, Senn H, Goldhirsch A, Forbes J, Thürlimann B, Marini G, Galligioni E, Gelber R, Castiglione-Gertsch M, Peterson H, Coates A, Hürny C, Rudenstam C. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). British journal of cancer 1998; 78:686-93.
Sep 1, 1998Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)
Sep 1, 1998British journal of cancer 1998; 78:686-93
Bernhard J, Senn H J, Goldhirsch A, Forbes J F, Thürlimann Beat, Marini G, Galligioni E, Gelber R D, Castiglione-Gertsch M, Peterson H F, Coates A S, Hürny C, Rudenstam C M